Advanz Pharma   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Mississauga Canada (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2010
NCT00867230
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ADVANZ PHARMA | at the request of Concordia Laboratories Inc. | CONCORDIA | Concordia Healthcare | Concordia Laboratories Inc. | CONCORDIA LABS INC | Concordia Pharmaceuticals | Concordia Pharmaceuticals, Inc | Concordia Pharmaceuticals Inc., Barbados | CONCORDIA PHARMS INC

Active Ingredients

Marketed Drugs (16)

Key: Advanz Pharma (15) Acquired (1)

alfuzosin (uroxatral) (2003)

alitretinoin (panretin) (1999)

clonidine (catapres) (2009)

digoxin (lanoxin) (1997)

hydrochlorothiazide (esidrix) (2006)

hydroxychloroquine (plaquenil) (1955 NDA)

metoprolol (lopressor) (2006)

nilutamide (nilandron) (1996)

phenoxybenzamine hydrochloride (dibenzyline) (1953 NDA)

pilocarpine (ocusert) (1994)

porfimer (photofrin) (1995 NDA)

prednisolone (hydeltra) (2000)

sodium polystyrene sulfonate (kayexalate) (1958 NDA)

tranylcypromine (parnate) (1961 NDA)

triamterene (dyrenium) (1964 NDA)

zonisamide (Zonegran) (2000)

Drugs in Phase 4 Trials (9)

Key: Advanz Pharma (1) Acquired (8)

acetylsalicylic acid (aspirin) (1 trial)

amiodarone (cordarone) (2 trials)

bremelanotide (Vyleesi) (2 trials)

clonidine (catapres) (1 trial)

ferrous sulfate (6 trials)

ferumoxytol (feraheme) (28 trials)

porfimer (photofrin) (6 trials)

sucroferric oxyhydroxide (velphoro) (3 trials)

vernakalant hydrochloride (12 trials)

Drugs in Phase 3 Trials (15)

Key: Advanz Pharma (2) Acquired (13)

butoconazole (Femstat) (2 trials)

ciclesonide (alvesco) (1 trial)

cisplatin (platinol) (1 trial)

clindamycin (cleocin) (2 trials)

dalbavancin (dalvance) (1 trial)

estradiol (progynon depot) (1 trial)

ferric carboxymaltose (Injectafer) (1 trial)

ferric fumarate (1 trial)

gemcitabine (gemzar) (2 trials)

hydroxyprogesterone (Delalutin) (4 trials)

iron sucrose (venofer) (2 trials)

oxypurinol (1 trial)

prasterone (intrarosa) (3 trials)

progestin (1 trial)

vitamin c (2 trials)

Drugs in Phase 2 Trials (16)

Key: Advanz Pharma (1) Acquired (15)

autologous mononuclear stem cell (2 trials)

autologous umbilical cord blood (2 trials)

carbomer (1 trial)

ciraparantag (8 trials)

danazol (danocrine) (1 trial)

dehydroepiandrosterone (1 trial)

digoxin immune fab (ovine) (DigiFab) (1 trial)

diphenhydramine (benadryl) (1 trial)

epoetin (Epogen) (1 trial)

glycerin (1 trial)

lidocaine (xylocaine) (1 trial)

mineral oil (1 trial)

nitroglycerin (transderm-nitro) (1 trial)

palm oil glyceride (1 trial)

polycarbophil (1 trial)

salirasib (1 trial)

Drugs in Phase 1 Trials (6)

Key: Advanz Pharma (1) Acquired (5)

autologous human cord blood derived stem cells (1 trial)

insulin lispro (humalog) (1 trial)

methylene blue (proveblue) (1 trial)

moxifloxacin (avelox) (1 trial)

ondansetron (zofran) (1 trial)

trans-farnesylthiosalicylic acid (1 trial)

Drugs in Other Trials (1)

Key: Advanz Pharma (0) Acquired (1)

sodium chloride (1 trial)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 85
  • # of Trial APIs: 47